CAV1 and amyotrophic lateral sclerosis: Upregulation of CAV1 is in development as a therapeutic tool (Head et al., 2011; US patent no. 8969077B2); our data suggest that this could be applied to genetically selected ALS patients in a personalized medicine approach.